ANNEXA-4

NEJM has been parceling out the results of the ANNEXA studies like the Harry Potter movie series.  I can’t wait for the final verdict on Xa-inhibitor reversals and the subgroup analysis on intracranial bleeds.  But for now, here is the study methodology:

ANDEXANET

  • bolus over 15-30 minutes + 2-hour infusion
  • For Apixaban or Rivaroxaban >7h before
    • 400mg bolus, 480mg infusion
  • For Enoxaparin, Edoxaban, Rivaroxaban <7h before or unknown time
    • 800mg bolus, 960mg infusion

 

Anti–Factor Xa Activity and Percent Change from Baseline in Patients Receiving Rivaroxaban and Apixaban (Efficacy Population).

Capture1.JPG

Capture2.JPG

 

Subgroup Analysis:

Capture.JPG

 

Reference:

Connolly, Stuart J. et al. “Andexanet Alfa For Acute Major Bleeding Associated With Factor Xa Inhibitors”. New England Journal of Medicine (2016).

Advertisements

Tagged: , , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: